Background {#Sec1}
==========

Bipolar disorder has substantial genetic and familiar overlap with schizophrenia and often share clinical features, including the presence of psychotic symptoms (Cardno and Owen [@CR11]; Moskvina et al. [@CR62]; Mamah and Barch [@CR55]; Fischer and Carpenter [@CR19]). Over 60% of bipolar disorder patients have had a lifetime history of at least one psychotic symptom (Keck et al. [@CR44]; Coryell et al. [@CR12]; Goodwin and Jamison [@CR29]). Some studies have also found that schizophrenia susceptibility genes are more commonly shared with psychotic bipolar patients, compared to bipolar patients without a psychotic disorder history (Moskvina et al. [@CR62]; Ivleva et al. [@CR41], [@CR42]; Green et al. [@CR30]; Potash [@CR69]; Tamminga et al. [@CR83]).

There has been continued interest in the use of neuroimaging to investigate intermediate phenotypes common across schizophrenia and bipolar disorder. The cortical structure of the brain is commonly quantitatively measured via gray matter volume, a measurement that is dependent on both cortical thickness and surface area of a region. These structural measures are thought to be heritable (Panizzon et al. [@CR67]) and can therefore provide insight into the genetic differences between patient populations. However, the surface area and cortical thickness appear to be genetically uncorrelated (Panizzon et al. [@CR67]). Thus, volume measurements, which combine aspects of both traits, are likely influenced by some combination of these genetic factors. Cortical thickness is thought to be dependent on the size, number, and arrangement of neurons and neuroglia in the cortex (Hatton et al. [@CR37]; Goldman-Rakic [@CR28]; Kuperberg et al. [@CR47]; Rakic and Caviness [@CR71]; Winkler et al. [@CR89]). As such, cortical thinning relative to normal populations has implications about the preservation of, or lack thereof, network architecture in the cortex. To the extent abnormal function in cortical and subcortical networks, which are thought to be perturbed in both diseases (Uhlhaas [@CR85]; Hulshoff Pol et al. [@CR40]; Menon [@CR61]), can be explained by abnormality of structure, the region-specific nature of cortical thinning could provide insight into differential developmental trajectories of brain disorders (Fischl et al. [@CR21]; Fischl and Dale [@CR20]).

Several brain studies investigating cortical structure have been conducted in schizophrenia and bipolar disorder patients. A meta-analysis of voxel-based morphometric studies in schizophrenia and bipolar disorder identified overlap of gray matter deficits in paralimbic cortical regions (including the anterior cingulate and insula) across the two diagnoses, with schizophrenia patients showing more extensive cortical deficits, also including neocortical and limbic regions (Ellison-Wright and Bullmore [@CR17]). A recent large meta-analysis by the ENIGMA schizophrenia working group found widespread cortical thinning in schizophrenia, as well as reduced surface area (van Erp et al. [@CR86]). Similarly, Rimol et al. ([@CR75]) found widespread cortical thinning and circumscribed cortical area reductions in schizophrenia patients, but not in bipolar disorder patients. However, the largest study of cortical thickness and surface area in bipolar disorder was conducted within the ENIGMA Consortium, and involved 2447 adult bipolar disorder patients (Hibar et al. [@CR38]). These authors found cortical thinning in frontal, temporal and parietal regions, as well as an association of reduced cortical surface area with psychosis history (Hibar et al. [@CR38]).

Heterogeneity in patient populations studied can influence the structural imaging findings observed (Zhang et al. [@CR93]). Thus, studying more homogenous populations may provide greater understanding of cortical thickness in disease. For example, investigating a wide age range of subjects can introduce confounds unrelated to the illness and associated with older age. Studying cortical thickness in younger and older bipolar disorder populations separately, have provided additional insights into the disease, showing substantial cortical thinning only in the older bipolar patients (Hibar et al. [@CR38]). Studying the clinical subtypes separately, can also be valuable. Patients with bipolar I disorder and bipolar II disorder are sometimes pooled as one group, despite the former representing a subtype with longer duration clinical episodes ("mania") than the latter ("hypomania") (American_Psychiatric_Association [@CR6]). Significant reductions in cortical volume and thickness however has been reported by some authors to be limited to bipolar I disorder patients (Maller et al. [@CR54]; Abe et al. [@CR1]; Rimol et al. [@CR74]). Finally, separating bipolar patients based on psychotic disorder histories often show differential effects, usually with the psychotic bipolar patients showing structural changes more closely related to that of schizophrenia patients (Strasser et al. [@CR81]; Mamah et al. [@CR58]; Womer et al. [@CR90]).

The current study compares cortical thickness between young adult (aged 18--30 years) control subjects and patients with schizophrenia, psychotic bipolar I disorder and non-psychotic bipolar I disorder. Bipolar disorder subjects all had a history of hyperthymic manic episodes, while patients with a history of exclusively irritable manic episodes were excluded. In addition, none of our participants met criteria for a substance use disorder in the past 6 months of assessment, to minimize substance related effects on cortical thickness. We hypothesized that patterns of cortical thinning in schizophrenia patients will share some similarity with psychotic but not non-psychotic bipolar disorder patients.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

All participants provided written informed consent and experimental procedures were approved by the Washington University School of Medicine institutional review board. Four diagnostic groups were included in the current study: healthy controls (CON; n = 40), schizophrenia (SCZ, n = 52), psychotic bipolar I disorder (PBD, n = 49) and non-psychotic bipolar I disorder (NPBD, n = 24). Participant groups were diagnosed on the basis of a consensus between a research psychiatrist and a trained research assistant who used the Structured Clinical Interview for DSM-IV Axis I Disorder (First et al. [@CR18]; Lobbestael et al. [@CR51]). CON subjects were required to have no lifetime history of psychotic or mood disorders. Bipolar (BD) participant patients were required to meet DSM-IV criteria for Bipolar I Disorder and were classified as psychotic BD if the participant had a psychotic event over the course of their lifetime, as assessed via the Structured Clinical Interview for the DSM (SCID). All psychotic events were reported to have occurred during manic episodes in bipolar participants. Participants were excluded if they: (a) met DSM-IV criteria for substance dependence or severe/moderate abuse during the prior 6 months; (b) had a clinically unstable or severe general medical disorder; or (c) had a history of head injury with documented neurological sequelae or loss of consciousness. Additionally, to minimize clinical heterogeneity within the BD group, only participants with a history of euphoric mania (versus mania characterized by primarily irritable mood) were included in the study.

Table [1](#Tab1){ref-type="table"} shows demographic data across the four participant groups. All patients were on stable medication for at least 4 weeks prior to assessment. Based on the results of the Young Mania Rating Scale (YMRS), the majority of bipolar participants were euthymic at the time of admission into the study. Four participants (3 PBD, 1 NPBD) scored between 13 and 20 suggesting a potential case of hyper- or hypomania. Three participants (2 PBD, 1 NPBD) scored above 20 indicating a probable case of hyper- or hypomania (Young et al. [@CR91]; Marchand et al. [@CR59]). The YMRS was only collected for bipolar patients. The average duration of illness for the psychotic bipolar group was 7.87 years while the average duration of illness for the non-psychotic group was 8.58 years.Table 1Demographics and Clinical InformationCharacteristicsCON (n = 40)SCZ (n = 52)PBD (n = 49)NPBD (n = 24)Mean age (SD)24.9 (5.0)26.1 (4.1)25.3 (3.7)26.2 (3.7)Sex (%) Male20 (50.0)38 (73.1)20 (40.8)8 (33.3) Female20 (50.0)14 (26.9)29 (59.2)16 (66.7)Race (%) Asian2 (5.0)01 (2.0)2 (8.3) Black20 (50.0)27 (51.9)13 (26.5)2 (8.3) Hispanic003 (6.1)0 White18 (45.0)25 (48.1)30 (61.2)18 (75.0) Multiracial002 (4.1)2 (8.3)Handedness (%) Left4 (10.0)2 (3.8)4 (8.2)3 (12.5) Right36 (90.0)50 (96.2)45 (91.8)21 (87.5)History of use disorder (%)^a^ Alcohol4 (10.0)17 (32.7)23 (46.9)12 (50.0) Cannabis021 (40.4)17 (34.7)6 (25.0) Stimulant1 (2.5)1 (1.9)1 (2.0)0 Opioid01 (1.9)2 (4.1)0 Cocaine006 (12.2)1 (4.2) Hallucinogen002 (4.1)1 (4.2)Psychotropic medication (%) Typical antipsychotic08 (13.6)3 (6.1)0 Atypical antipsychotic037 (72.5)30 (62.2)6 (25.0) SSRI015 (29.4)24 (49.0)10 (41.7) Other antidepressants^b^03 (5.8)12 (24.5)7 (29.2) Stimulant004 (8.2)3 (12.5) Mood stabilizer011 (21.6)33 (67.3)18 (75.0) Benzodiazepines01 (2.0)20 (40.8)6 (25.0) Anticholinergic008 (16.3)2 (8.3) None40 (100.0)13 (25.5)6 (12.2)1 (4.2)Symptom domains (SD) SAPS^c^0.25 (.2)3.56 (3.0)1.35 (1.9)0.42 (0.8) Hallucination subscale01.40 (1.8)0.39 (0.9)0 Delusion subscale0.05 (.221)2.12 (1.4)0.96 (1.3)0.42 (0.8) SANS^d^2.30 (2.3)10.25 (3.9)3.18 (3.8)3.42 (2.4) Flat Affect subscale0.08 (0.4)1.85 (1.3)0.59 (0.9)0.71 (1.2) Alogia subscale0.05 (0.3)1.23 (1.8)0.16 (0.5)0.13 (0.4) Anhedonia subscale0.38 (0.8)2.48 (1.1)1.31 (1.4)1.04 (1.1) Amotivation subscale0.73 (1.1)3.02 (1.0)1.24 (1.4)0.92 (1.2) Attention subscale1.08 (1.3)1.67 (1.3)0.88 (1.1)0.63 (1.0)^a^Other than for nicotine use disorder, participants did not meet criteria for a use disorder in the last 6 months^b^Refers to antidepressants other than selective serotonin reuptake inhibitors (SSRI)^c^Maximum possible score on the Structured Assessment of Positive Symptoms (SAPS) is 16^d^Maximum possible score on the Structured Assessment of Negative Symptoms (SANS) is 20

Clinical assessment {#Sec4}
-------------------

Symptoms were assessed using the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS). Specific subscale scores were summed to derive measures of positive symptoms (i.e. hallucination, delusion) and negative symptoms (i.e. flat affect, alogia, anhedonia, attention and amotivation subscales). Disorganized symptoms were not included in SAPS scores so as to only reflect the presence of positive symptoms.

Image and cortical thickness acquisition {#Sec5}
----------------------------------------

Magnetic resonance (MR) scans were obtained using a Siemens (Erlangen, Germany) 3T Tim TRIO Scanner at Washington University Medical School. T1-weighted images were acquired using a sagittal MPRAGE 3D sequence (TR = 2400 ms, TE = 3.16 ms, flip = 8°; voxel size = 1 × 1 × 1 mm).

Cortical thickness of 34 brain cortical regions for each hemisphere were obtained using FreeSurfer version 5.1.0 software (Fischl et al. [@CR21]; Dale et al. [@CR13]). Gray-matter (GM) and white-matter (WM) boundaries were reconstructed in order to estimate the distance between those surfaces across the cortex in order to calculate the cortical thickness (Dale et al. [@CR13]; Han et al. [@CR32]; Rosas et al. [@CR76]). Our preprocessing included automated skull stripping, removal of subcortical surfaces, transformation into Talairach space, and a spatial smoothing algorithm (Dale et al. [@CR13]). Measurements of intracranial volume (ICV) were determined via the automated Freesurfer pipeline. These surfaces were then inflated into spheres in order to be registered to a common space via an automated procedure based on identification of cortical features identified in a predefined atlas (Fischl et al. [@CR21]). Thickness for each region of interest (ROI) was calculated on a per-vertex basis based on the distance between closest points between gray and white-matter surfaces and then averaged across vertices within each region of interest (Fischl et al. [@CR21]; Dale et al. [@CR13]).

Statistical analysis {#Sec6}
--------------------

Statistical analyses were performed using IBM's SPSS software (IBM SPSS Statistics for Macintosh, Version 24.0, Armonk, NY). We examined group differences in SAPS and SANS measures using a multivariate analysis of covariance, covarying for age and sex. Differences in cortical thickness between subjects of different diagnostic groups were initially tested using a repeated measures analysis of covariance, covaried for age, sex, and ICV, treating hemisphere and region as repeated-measures. ICV was used here as a covariate given past evidence of cranial size differences in individuals with schizophrenia (Ward et al. [@CR88]). This repeated-measures test revealed no main effect of hemisphere. Thus, subsequent testing was performed on cortical thickness values averaged across hemisphere in order to reduce the number tests for multiple comparisons considerations. We then tested for univariate effects of diagnostic group on cortical thickness within each region, with post hoc analyses of pairwise differences in groups in regions showing a univariate effect. To assess the relationship between clinical variables and cortical thickness, we performed a set of linear regressions to predict SAPS and SANS scores for each ROI. Included in these models were predictors for age, sex, ICV as well as dummy predictors for SCZ, PBD, and NPBD group membership in addition to a cortical thickness regressor. Given the number of regions tested, multiple comparisons corrections are noted when performed.

Results {#Sec7}
=======

Clinical measures {#Sec8}
-----------------

Based on multivariate testing, there was a significant main effect of diagnosis (F~(6,310)~ = 20.530, Wilk's Λ = 0.512, *p* \< 0.001, η^2^ = 0.284) after controlling for age and sex, indicating a difference in SAPS and SANS scores between groups. Differences in scores were driven by higher ratings in the SCZ and PBD groups relative to controls (CON) in the SAPS data, and SCZ relative to all other groups in the SANS scores (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Clinical measures of positive and negative symptoms by diagnosis. (left) Relationship between positive symptoms by diagnosis as assessed by SAPS. (right) Negative symptom scores as assessed by SANS by diagnosis. Significant pairwise comparisons shown in both figures, Bonferroni corrected for multiple comparisons. Error bars represent within-group standard error

Group analysis of cortical thickness {#Sec9}
------------------------------------

Covarying for sex, age, and ICV, a repeated-measures test of cortical thickness showed a significant main effect of diagnosis (F~(3,158)~ = 5.664, *p* = 0.001, η^2^ = 0.058; Fig. [2](#Fig2){ref-type="fig"}) and region (F~(33,514)~ = 23.074, *p* \< 0.001, η^2^ = 0.127), but no effect of hemisphere (F~(1,158)~ = 3.650, *p* = 0.057, η^2^ = 0.021). We observed a group by hemisphere interaction (F~(3,158)~ = 8.879, *p* \< 0.001, η^2^ = 0.144), driven by decreased right hemisphere thickness in the CON and SCZ groups relative to BD groups.Fig. 2Average cortical thickness per hemisphere by diagnosis. In repeated-measures testing, a significant main effect of diagnosis was observed, with no significant main effect of hemisphere. Significance comparisons represent pairwise contrasts between diagnostic groups. Significance values greater than 0.05 not shown. Pairwise comparisons were Bonferroni corrected for multiple comparisons. Error bars represent within-group standard error

Further tests of cortical thickness averaged values across hemisphere to produce 34 cortical regions of interest to reduce the number of tests performed, given the lack of a main effect of hemisphere. Table [2](#Tab2){ref-type="table"} shows the results of 34 univariate tests, one for each region. After Bonferroni correction, significant effect of diagnosis was observed for the superior frontal cortex, paracentral cortex, the fusiform gyrus, as well as the caudal anterior and posterior portions of the cingulate. For visualization purposes, mean, z-scored cortical thickness values of the 34 cortical regions are depicted in Fig. [3](#Fig3){ref-type="fig"}.Table 2Estimated marginal meansROICONSCZPBDNPBDF~(3,156)~ (p value)Frontal1. Frontal pole2.7362.6752.6502.6961.279 (0.284)2. Superior fontal*2.6972.6452.7232.7536.281* (*\< 0.001*)3. Rostral middle frontal2.2842.3022.3202.3552.239 (0.062)4. Caudal middle frontal2.5692.5162.5642.5773.091 (0.029)5. Pars opercularis2.6122.5902.5992.6451.660 (0.178)6. Pars triangularis2.4832.4562.4542.4470.353 (0.787)7. Pars orbitalis2.6542.6072.6012.6181.254 (0.292)8. Precentral2.4472.5292.5912.5584.490 (0.005)9. Paracentral*2.4312.3692.4642.4587.764* (*\< 0.001*)10. Lateral orbitofrontal2.5372.5192.5032.5842.274 (0.082)11. Medial orbitofrontal2.3272.3082.3302.3952.019 (0.114)Parietal12. Superior parietal2.2762.2092.2252.2592.153 (0.096)13. Inferior parietal2.5162.4372.4882.5265.136 (0.002)14. Supramarginal2.5852.5222.5692.5754.586 (0.004)15. Postcentral2.1102.1072.0892.0740.512 (0.675)16. Precuneus2.4472.3882.3952.4552.569 (0.062)Temporal17. Temporal pole3.6703.6183.7513.8103.095 (0.029)18. Superior temporal2.8682.8172.8272.8542.676 (0.049)19. Middle temporal2.9372.8392.8672.9093.841 (0.011)20. Inferior temporal2.8192.7102.7562.7674.029 (0.009)21. Bank Sup. Temp. Sulcus2.6272.5662.5422.5681.438 (0.234)22. Fusiform*2.7442.6632.7262.7787.476* (*\< 0.001*)23. Transverse temporal2.5202.4882.4622.4942.351 (0.074)24. Parahippocampal2.8082.7182.7702.7952.740 (0.045)25. Entorhinal3.4283.3593.5343.5213.486 (0.017)Occipital26. Lateral occipital2.2422.1712.1842.1932.274 (0.082)27. Lingual2.0972.0532.0192.0300.852 (0.467)28. Cuneus1.9281.8891.8781.9171.799 (0.150)29. Pericalcarine1.7251.7031.7341.6180.446 (0.721)Cingulate30. Rostral Ant. cingulate2.7762.7772.8512.8562.501 (0.062)31. Caudal Ant. cingulate*2.5252.5542.5602.5686.441* (*\< 0.001*)32. Posterior cingulate*2.5082.4682.4992.6157.062* (*\< 0.001*)33. Isthmus of cingulate2.4392.4092.4192.4821.321 (0.270)Insula34. Insula3.0503.0013.0543.0493.858 (0.011)Values indicate estimated means of subject groups, controlled for age, sex, race and total intracranial volume. Significance values are uncorrected for multiple comparisons. Italicized regions were significant after Bonferroni correcting for 34 comparisons*ROI* region of interest, *CON* control, *SCZ* schizophrenia, *PBD* psychotic bipolar disorder, *NPBD* non-psychotic, bipolar disorder, *Temp.* temporal, *Sup.* superior, *Ant.* anterior Fig. 3Z-scored, average cortical thickness values per region of interest. Region of interest labels correspond to those identified in Table [2](#Tab2){ref-type="table"}. Z-scores were computed by using the mean and standard deviation of the control group as reference, and as such the healthy controls lie on the horizontal axis. Error bars represent within-group standard error

Results of post hoc analyses, comparing cortical thickness between individual groups in regions that showed an omnibus group effect (prior to Bonferroni correction), are shown in Table [3](#Tab3){ref-type="table"}. After Bonferroni correction, pairwise comparisons showed cortical thinning in SCZ participants relative to other groups, most notably in specific frontal, parietal and temporal regions. However, the thickness of the anterior cingulate cortex was increased in SCZ, PBD, and NPBD participants compared to CON participants. Cortical thickness in the posterior cingulate was larger in NPBD compared to CON participants. There were no other significant cortical thickness abnormalities in either PBD or NPBD compared to CON.Table 3Pair-wise cortical thickness comparisons by diagnostic groupROICON vs. SCZCON vs. PBDCON vs. NPBDSCZ vs. PBDSCZ vs. NPBDFrontal2. Superior fontalPBD \> SCZ\
*p *= 0.001NPBD \> SCZ\
*p *= 0.0044. Caud. Mid. frontalPBD \> SCZ\
*p *= 0.0338. PrecentralPBD \> SCZ\
*p *= 0.0039. ParacentralCON \> SCZ\
*p *= 0.004PBD \> SCZ\
*p *\< 0.001NPBD \> SCZ\
*p *= 0.004Parietal13. Inferior parietalCON \> SCZ\
*p *= 0.033PBD \> SCZ\
*p *= 0.035NPBD \> SCZ\
*p *= 0.00314. SupramarginalCON \> SCZ\
*p *= 0.015PBD \> SCZ\
*p *= 0.009Temporal17. Temporal pole18. Sup. temporal19. Mid. temporalCON \> SCZ\
*p *= 0.027NPBD \> SCZ\
*p *= 0.03222. FusiformCON \> SCZ\
*p *= 0.032PBD \> SCZ\
*p *= 0.004NPBD \> SCZ\
*p *\< 0.00124. ParahippocampalNPBD \> SCZ\
*p *= 0.04225. EntorhinalCingulate31. Caud. Ant. cingulate*SCZ \> CON*\
*p = 0.028PBD \> CON*\
*p = 0.005NPBD \> CON*\
*p \< 0.001*32. Post. cingulate*NPBD \> CON*\
*p \< 0.001*NPBD \> SCZ\
*p *\< 0.001Insula34. InsulaNPBD \> SCZ\
*p *= 0.016Values shown reflect *p* values Bonferroni corrected for multiple comparisons for five comparisons within each region. Italicized values indicate regions that are smaller in control participantsBlank cells indicate a *p* value greater than 0.05 after correcting for multiple comparisons. No differences in PBD and NPBD groups was observed*ROI* region of interest, *CON* control, *SCZ* schizophrenia, *PBD* psychotic bipolar disorder, *NPBD* non-psychotic bipolar disorder, *Ant.* anterior, *Sup.* superior, *Post.* posterior, *Caud.* caudal, *Mid.* middle

Clinical relationships of cortical thickness {#Sec10}
--------------------------------------------

We performed linear regressions to predict SAPS and SANS scores based on cortical thickness, diagnostic group membership, and covariates (age, sex, and ICV). All regression models significantly predicted SAPS scores (F's~(7,157)~ \> 11.601, *p's* \< 0.001) and a diagnosis of SCZ (*p*'s \< 0.001) or bipolar disorder with psychotic symptoms (*p*'s \< 0.005) predicted higher SAPS. The partial correlations associated with the cortical thickness of each region, as well as the significance of those parameter estimates is shown in Table [4](#Tab4){ref-type="table"}. After Bonferroni correction for multiple (34) tests, two regions showed significant correlations with SAPS: the middle temporal gyrus (r = − 0.257) and the fusiform area (r = − 0.255). Several additional regions were significant prior to correction for multiple comparisons including frontal (pars triangularis, lateral orbitofrontal), parietal (inferior parietal, supramarginal, precuneus) and temporal (inferior temporal, bank of the superior temporal sulcus, entorhinal) areas.Table 4Partial correlations predicting SAPS scoresROIPartial correlation*p* valueFrontal1. Frontal pole0.0450.5692. Superior fontal− 0.0740.3523. Rostral middle frontal− 0.0260.7484. Caudal middle frontal− 0.1200.1335. Pars opercularis− 0.1410.0756. Pars triangularis− *0.1750.027*7. Pars orbitalis− 0.1670.0368. Precentral− 0.1170.1429. Paracentral− 0.1140.15410. Lateral orbitofrontal− *0.1630.040*11. Medial orbitofrontal− 0.0880.269Parietal12. Superior parietal− 0.0900.26013. Inferior Parietal− *0.2070.009*14. Supramarginal− *0.1720.030*15. Postcentral− 0.0560.48316. Precuneus− *0.1880.018*Temporal17. Temporal pole− 0.0990.21718. Superior temporal− 0.1070.17919. Middle temporal*− * ***0.257**0.001***20. Inferior temporal− *0.2460.002*21. Bank Sup. Temp. sulcus− *0.2170.006*22. Fusiform*− * ***0.255**0.001***23. Transverse temporal0.0400.61424. Parahippocampal− 0.0430.59125. Entorhinal− *0.1570.048*Occipital26. Lateral occipital− 0.1540.05327. Lingual− 0.1110.16228. Cuneus− 0.0370.64329. Pericalcarine− 0.0160.845Cingulate30. Rostral Ant. cingulate0.0280.73031. Caudal Ant. cingulate0.0740.35632. Posterior cingulate− 0.1150.15133. Isthmus of cingulate0.0120.882Insula34. Insula− 0.0650.417Values derived from linear regression predicting SAPS scores. Significance values are uncorrected for multiple comparisons. Italicized regions indicate significance prior to multiple comparisons correction. Bolditalic regions were significant after Bonferroni correcting for 34 comparisons*ROI* region of interest, *CON* control, *SCZ* schizophrenia, *PBD* psychotic bipolar disorder, *NPBD* non-psychotic, bipolar disorder, *Temp.* temporal, *Sup.* superior, *Ant.* anterior

All regression models also significantly predicted SANS scores (F's~(7,157)~ \> 23.780, *p's* \< 0.001), with SCZ (*p'*s \< 0.001) or psychotic BD (*p*'s \< 0.005) predicting higher SANS scores. After correcting for multiple comparisons, no region's cortical thickness predicted negative symptom scores. Partial correlations prior to multiple comparisons correction are shown in Table [5](#Tab5){ref-type="table"}. Regions that were significant prior to multiple comparisons correction included frontal (middle frontal gyrus), parietal (inferior parietal), and temporal (inferior temporal, fusiform) regions.Table 5Partial correlations predicting SANS scoresROIPartial correlation*p*-valueFrontal1. Frontal pole0.1310.0992. Superior fontal0.0810.3083. Rostral middle frontal*0.1910.016*4. Caudal middle frontal− 0.0140.8635. Pars opercularis− 0.0090.9156. Pars triangularis0.0670.3997. Pars orbitalis− 0.0610.4428. Precentral− 0.0120.8809. Paracentral0.0840.29510. Lateral orbitofrontal− 0.0850.28611. Medial orbitofrontal0.0960.229Parietal12. Superior parietal− 0.0470.55713. Inferior parietal− *0.1610.043*14. Supramarginal− 0.0590.45715. Postcentral0.0140.86316. Precuneus0.0010.994Temporal17. Temporal pole− 0.0850.28618. Superior temporal− 0.0190.81619. Middle temporal− 0.1080.17420. Inferior temporal− *0.1420.073*21. Bank Sup. Temp. sulcus− 0.0830.29622. Fusiform− *0.2170.006*23. Transverse temporal24. Parahippocampal− 0.0210.78925. Entorhinal− 0.0670.398Occipital26. Lateral occipital− 0.1140.15427. Lingual− 0.0050.94628. Cuneus− 0.0420.59929. Pericalcarine0.0380.631Cingulate30. Rostral Ant. cingulate0.050.53331. Caudal Ant. cingulate− 0.0120.88232. Posterior cingulate0.0550.49133. Isthmus of cingulate− 0.020.802Insula34. Insula0.050.532Values derived from linear regression predicting SANS scores. Significance values are uncorrected for multiple comparisons. Italicized regions indicate significance prior to multiple comparisons correction. No regions were significant after Bonferroni correcting for 34 comparisons*ROI* region of interest, *CON* control, *SCZ* schizophrenia, *PBD* psychotic bipolar disorder, *NPBD* non-psychotic, bipolar disorder, *Temp.* temporal, *Sup.* superior, *Ant.* anterior

Discussion {#Sec11}
==========

Our study investigated cortical thickness in young adult patients with schizophrenia and relatively homogenous clinical subgroups of bipolar I disorder patients, comprising of psychotic---(PBD) and non-psychotic (NPBD) patients with hyperthymic mania histories. We found that SCZ participants had significant cortical thinning relative to CON and BD most significantly in the frontal (i.e. paracentral), parietal (i.e. inferior parietal, supramarginal), and temporal (i.e. middle temporal, fusiform) cortices. Our results are consistent with that of most other studies which found cortical thinning in SCZ relative to control populations across a wide range of cortical regions, usually including parts of the frontal and temporal cortex (van Erp et al. [@CR86]; Rimol et al. [@CR75]; Sugihara et al. [@CR82]; Knochel et al. [@CR45]; Besteher et al. [@CR8]; Nenadic et al. [@CR66]; Goldman et al. [@CR27]). A recent meta-analysis of 4474 SCZ subjects found that the largest effect sizes for lower cortical thickness compared to controls were present in the fusiform, inferior frontal (pars opercularis), lateral orbitofrontal, temporal (inferior/medial/superior), parahippocampal, insula, isthmus cingulate, and the posterior cingulate cortices (van Erp et al. [@CR86]). Despite some inconsistencies in the specific affected regions across schizophrenia studies, which likely reflects the biological heterogeneity of patients and methodological differences, cortical thinning is considered a key pathology underlying schizophrenia. Interestingly, we also found increased cortical thickness in an isolated region---the anterior cingulate cortex (ACC)---in the schizophrenia group, as well as in both groups of bipolar disorder subjects. The ACC is a brain region critical for integrating cognitive and emotional functions in support of adaptive, goal-directed behavior (Devinsky et al. [@CR15]). Increased ACC thickness in our subjects do not appear to be driven primarily by their relatively young age, as ACC thinning has also been seen in youth at clinically high risk for developing schizophrenia (Jung et al. [@CR43]; Yucel et al. [@CR92]). These findings in our patient groups differ from other studies that found gray matter reduction in the ACC in schizophrenia (Fornito et al. [@CR22]; Bouras et al. [@CR9]; Hanford et al. [@CR33]). However, increased ACC thickness has been reported in male first episode psychosis in bipolar disorder (Fornito et al. [@CR23]). These authors suggested that hypertrophy of regions critical for regulating the HPA axis, including the ACC, amygdala and pituitary gland, in early psychosis may be associated with an elevated stress response, which ultimately results in volumetric contraction with chronic illness. A few other authors also found increased ACC thickness in either first-episode (Adler et al. [@CR3]) or chronic (Adler et al. [@CR2]; Bearden et al. [@CR7]) bipolar disorder, which was also been attributable to lithium effects in one study (Bearden et al. [@CR7]) but not others (Fornito et al. [@CR23]; Adler et al. [@CR3]). Taken together, these findings suggest that while widespread cortical thinning is pathognomonic of schizophrenia, increased ACC thickness in some schizophrenia cohorts may reflect a hyperfunctional abnormality that produces an excessive stress response.

Contrary to our hypothesis, we did not find similar cortical thinning in PBD as we found in schizophrenia. Cortical thickness in both PBD and NPBD were comparable into controls, other than the increased ACC discussed above. It is notable that several other regions were larger in bipolar patients than in controls, albeit non-significantly. While these findings differ from those from a recent systematic review of bipolar disorder which reported cortical thinning in bipolar disorder (Hanford et al. [@CR33]), normal cortical thickness have also been reported (Rimol et al. [@CR74], [@CR75]). The ENIGMA Consortium conducted the largest cortical analysis of bipolar disorder patients, involving 6503 subjects and found bilateral frontal, temporal and parietal cortical thinning, especially in the left pars opercularis, fusiform gyrus and rostral middle frontal cortex (Hibar et al. [@CR38]). When cortical thinning is observed in bipolar disorder, it is however not as pronounced as it is in schizophrenia and sometimes involves different brain regions (Knochel et al. [@CR45]). Cortical thinning found in some bipolar disorder studies but not others appears to be due to differences in the populations studied. For example, older age and illness chronicity would be expected to lead to greater cortical thinning in bipolar disorder patients. Our study involved bipolar disorder subjects who on average, were in their mid-twenties, while most other bipolar studies include older populations. The ENIGMA bipolar study included older patients (grand mean age across sites was 37.5 years) found notably greater cortical thinning when comparing older BD patients to controls, than when younger bipolar patients were compared to controls (Hibar et al. [@CR38]). Thus, cortical thinning may be a later presentation of bipolar disorder, which would not be evident in younger adults. Our bipolar disorder population also consisted of a more homogenous clinical cohort than those in most other studies, including only bipolar 1 disorder patients with hyperthymic manic histories. Although not directly investigated, it is plausible that bipolar disorder with hyperthymic mania may be associated with less cortical thinning than with irritable mania. Future studies comparing bipolar disorder patients based on their manic presentation, may clarify their relationship to brain structure. Finally, differences in cortical findings across studies may be related to differences in the medication and recreational drug use of the patient cohorts. Psychotropic medications used in bipolar disorder have been associated with both increased cortical thickness (e.g. lithium) (Giakoumatos et al. [@CR24]) and cortical thinning (e.g. typical antipsychotics) (van Haren et al. [@CR87]). Similarly, recreational substances can also exacerbate cortical thinning in patients (Hartberg et al. [@CR36]). Our study design excluded those with a significant substance use comorbidity (i.e. substance use disorder in last 6 months), and therefore may have represented a healthier cohort with less cortical abnormality.

We did not find any notable differences between our clinical subgroups of bipolar disorder subjects. Cortical and subcortical volumetric deficits have been reported in psychotic compared to nonpsychotic bipolar disorder (Strasser et al. [@CR81]; Altamura et al. [@CR5]). However, consistent with our study, the ENIGMA group did not find a relationship of psychosis history and cortical thickness in bipolar subjects, although they reported an association of psychosis with surface area in isolated brain regions (Hibar et al. [@CR38]). Thus, cortical surface or volume, which were not investigated in our study, may be more sensitive in discriminating these clinical subtypes of bipolar disorder. PBD has been reported to represent a clinical construct more closely related to schizophrenia than NPBD, based on clinical presentation, familial and genetic overlap (Moskvina et al. [@CR62]; Ivleva et al. [@CR41], [@CR42]; Green et al. [@CR30]; Potash [@CR69]; Tamminga et al. [@CR83]). PBD patients also show greater cognitive dysfunction compared to NPBD, approximating that seen in schizophrenia (Martinez-Aran et al. [@CR60]; Simonsen et al. [@CR78]; Bourne et al. [@CR10]).

Our results showed that the cortical thickness of several brain regions correlated with measures of positive and negative symptoms, although only relationships between temporal regions and positive symptoms survived multiple comparisons correction. The observed correlations however may have been minimized by confounders, which were not adequately corrected. For example, the recorded SAPS and SANS scores reflect symptom severity within the previous 2 weeks, and often fluctuate over time. Additionally, dimensional ratings for depression were not collected for the current study. Considering that the period between symptom assessment and brain scanning varied across patients and were in some cases lengthy (median: 14 days; mean: 19 days), clinical symptoms during scanning may not be properly captured by our instruments. In the future, studying associations with clinical measures of chronic symptoms severity, such as the Washington Early Recognition Affectivity and Psychosis (WERCAP) Screen (Hsieh et al. [@CR39]; Mamah et al. [@CR57]), may be more accurate in uncovering brain-behavior relationships.

Numerous factors may contribute to cortical thinning, including changes in the number, density and arrangement of cells in the cortical sheet (Hatton et al. [@CR37]; Goldman-Rakic [@CR28]; Kuperberg et al. [@CR47]; Rakic and Caviness [@CR71]). Post-mortem examination of SCZ have shown reduced neuronal size and neuropil (Rimol et al. [@CR75]; Tandon et al. [@CR84]; Harrison [@CR34]). Others have reported decreases in glial density and proliferation, indicating a relative lack of gliosis (Tandon et al. [@CR84]; Harrison [@CR34]; Phillips et al. [@CR68]) as well as an increase in synaptic apoptosis leading to reduced synaptic integrity in pyramidal neurons (Glantz and Lewis [@CR25]). Decreased glial density, reduced neuronal size, and synaptic degeneration have also been observed in BD to a lesser extent than in SCZ (Tandon et al. [@CR84]; Harrison [@CR35]). Most of these changes are believed to be neurodevelopmental in origin (Harrison [@CR34], [@CR35]; Phillips et al. [@CR68]; Rapoport et al. [@CR72]; Lewis and Levitt [@CR48]) supported by reports of cortical thinning in medication naïve subjects (Narr et al. [@CR63], [@CR64]; Lyoo et al. [@CR53]), as well as prior to disease onset (Ellison-Wright and Bullmore [@CR17]; Tandon et al. [@CR84]; Harrison [@CR34]) and in unaffected relatives (Goghari et al. [@CR26]).

There are some limitations to our study. Firstly, medications can influence cortical thickness, which could disproportionately affect SCZ and BD participants. Considering our sample size and the complexity of medications and doses, our current study was not adequately designed to decipher medication related effects. Typical antipsychotics, such as haloperidol, have been found to cause regional cortical thinning across wide ranges of cortical regions including frontal, temporal, and parietal areas (Dazzan et al. [@CR14]; Lieberman et al. [@CR49]; Navari and Dazzan [@CR65]), in addition to increased basal ganglia volumes (Dazzan et al. [@CR14]; Smieskova et al. [@CR79]). Atypical antipsychotics have been associated with more muted cortical thinning compared to typical antipsychotics (Navari and Dazzan [@CR65]; Mamah et al. [@CR56]), and antidepressants (Duman and Monteggia [@CR16]; Lim et al. [@CR50]) and lithium (Bearden et al. [@CR7]; Hafeman et al. [@CR31]) have neurotrophic effects, which are believed to underlie symptomatic improvement. Secondly, our study results may also have been influenced by gender disparity across groups. Our subjects consisted of more males than females in the SCZ group, and more females in the BD groups. Thicker cortices have been found in regionally in women compared to men in some (Sowell et al. [@CR80]; Koolschijn and Crone [@CR46]; Savic and Arver [@CR77]) but not all (Raznahan et al. [@CR73]) studies. Sex related differences have also been reported in cortical surface area, as well as neuronal and synaptic density (Rabinowicz et al. [@CR70]; Luders et al. [@CR52]; Alonso-Nanclares et al. [@CR4]). While our statistical design, treating gender as a covariate, may reduce some of this potential confound, matching studies by gender would lead to more accurate results. Finally, our study was not well powered to investigate group differences in each individual brain region. In order to reduce the number of tests performed when examining relationships between cortical thickness and symptom measures, we collapsed across hemisphere. While cortical thickness in most regions correlated across hemispheres, a group by hemisphere interaction was observed. Thus, group differences in regional cortical thickness in our patients may be specific to individual hemispheres.

Conclusions {#Sec15}
===========

In conclusion, our studies investigated cortical thickness in a relatively homogenous groups of young adult schizophrenia patients and bipolar I disorder patients with hyperthymic manic histories. Regions of decreased cortical thickness were observed in schizophrenia patients, but not in either psychotic or non-psychotic bipolar patients. Thickness of the anterior cingulate cortex was increased in all patient groups. Clinical and demographic heterogeneity in patient populations may explain inconsistent findings across studies.
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